Andreadis, C., Avivi, I., Goldschmidt, N., Townsend, W., Bastos-Oreiro, M., Avigdor, A., Riedell, P., Tzoran, I., Eyre, T., McKay, P., Abrisqueta, P., Barca, E. G., Garcia-Sancho, A. M., Galimberti, S., Kwan, A., Relf, J., Leung, W., Mussai, F., Ma, C., Petel, A., Mueller, P., Hou, X., Fox, C. (2025). Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). Blood. https://doi.org/10.1182/blood-2025-66